Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Gibco
PeproGMP® Human VEGF-165 Recombinant Protein, PeproTech®
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
FIGURE: 1 / 1
PeproGMP® Human VEGF-165 Protein (GMP100-20-50UG) in Functional
Product Details
GMP100-20-50UG
Species
Expression System
Amino acid sequence
Molecular weight
Class
Type
Purity
Endotoxin concentration
Activity
Conjugate
Form
Purification
Contains
Storage conditions
Shipping conditions
Product Specific Information
Recombinant Human VEGF 165 is a 38.2 kDa, disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains.
Additional product information and specifications are provided on the Certificate of Analysis.
All PeproGMP® products are manufactured using animal-derived component free materials.
Product Description/Intended Use: PeproTech GMP recombinant proteins are manufactured for use as ancillary materials by applying applicable principles of GMP and quality control requirements from USP (United States Pharmacopeia) Chapter <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products.
Target Information
The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.
For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.
References (0)
Bioinformatics
Protein Aliases: H-VEGF-165; L-VEGF; M-VEGF-165; Vascular endothelial growth factor A, long form; vascular endothelial growth factor A121; vascular endothelial growth factor A165; Vascular permeability factor; VEGF165; VPF
Gene Aliases: MVCD1; VEGF; VEGFA; VPF
UniProt ID: (Human) P15692
Entrez Gene ID: (Human) 7422
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support